Evidence map›Paper›PMID 34120461›Full record

ReviewPharmacogenomics2021

Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma.

Caroline Yk Fong, Ian Chau

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacogenomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Caroline Yk FongThe Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK.ORCID 0000-0002-4409-9466
Ian ChauThe Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK.ORCID 0000-0003-0286-8703
Royal Marsden NHS Foundation Trust · GB

Funding

Department of Health
6 · The paper itself

Abstract

Advanced esophago-gastric (OG) adenocarcinomas have a high mortality rate and new therapeutic options are urgently required. Despite recent advances in understanding the molecular characteristics of OG cancers, tumor heterogeneity poses a challenge in developing new therapeutics capable of improving patient outcomes. Consequently, chemotherapy remains the mainstay of systemic treatment, with the HER2 being the only predictive biomarker routinely targeted in clinical practice. Recent data indicate that immunotherapy will be incorporated into first-line chemotherapy, but further research is required to refine patient selection. This review will summarize the clinical strategies being evaluated to utilize our knowledge of predictive biomarkers with reference to novel therapeutics, and discuss the barriers to implementing precision oncology in OG adenocarcinoma.

Indexed as

AdenocarcinomaBiomarkersBiomarkers, TumorCamptothecinErb-b2 Receptor Tyrosine KinasesEsophageal NeoplasmsHumansImmune Checkpoint InhibitorsImmunoconjugatesImmunotherapyPrecision MedicineStomach NeoplasmsTrastuzumabBiomarkersBiomarkers, TumorCamptothecinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmune Checkpoint InhibitorsImmunoconjugatesTrastuzumabtrastuzumab deruxtecanbiomarkers of responseesophageal canceresophago-gastric adenocarcinomagastric cancergastro-esophageal junction cancerprecision oncologypredictive biomarkerstargeted therapy

Identifiers

PMID34120461
PMCPMC8265282
OpenAlexW3167746295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.